Study guide

4.1 Co-Occurring Psychiatric Disorders & Integrated Screening

NAADAC Master Addiction Counselor MAC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & MAC Exam Overview

1.1 About the MAC Exam, Eligibility & Kryterion Format 1.2 Content Blueprint, Scoring Standards & Study Strategy

2 Chapter 2: Orientation to the Treatment Process & Continuum of Care

2.1 Patient Intake, Engagement & Screening Workflows 2.2 ASAM Criteria & Levels of Care Continuum 2.3 Referral Systems, Service Coordination & Patient Advocacy 2.4 Client Rights, Program Orientation & Informed Consent

3 Chapter 3: Biopsychosocial Assessment & Diagnostic Evaluation

3.1 Comprehensive Biopsychosocial Assessment Architecture 3.2 DSM-5-TR Diagnostic Criteria for Substance Use Disorders 3.3 Standardized Screening & Assessment Tools (AUDIT, CAGE, DAST, GAIN) 3.4 The Six ASAM Assessment Dimensions & Risk Rating

4 Chapter 4: Co-Occurring Disorders & Differential Diagnosis

4.1 Co-Occurring Psychiatric Disorders & Integrated Screening 4.2 Trauma-Informed Assessment & PTSD Screening 4.3 Suicide Risk Assessment & Immediate Safety Planning 4.4 Cultural Competence & Diversity in Clinical Assessment

5 Chapter 5: Individualized Treatment Planning & Goal Setting

5.1 Individualized Treatment Plan Development & Problem Identification 5.2 Formulating SMART Goals & Measurable Objectives 5.3 Matching ASAM Dimensions to Levels of Care & Interventions 5.4 Patient-Centered Planning, Readiness to Change & Client Autonomy

6 Chapter 6: Treatment Implementation, Care Coordination & Review

6.1 Continuous Treatment Plan Review & Progress Evaluation 6.2 Interprofessional Collaboration & Multidisciplinary Care 6.3 Case Management & Social Determinants of Recovery 6.4 Discharge Planning, Continuing Care & Transition Management

7 Chapter 7: Individual & Group Addiction Counseling Practices

7.1 Core Individual Counseling Micro-Skills & Therapeutic Alliance 7.2 Group Counseling Dynamics, Process & Facilitation 7.3 Family Systems, Codependency & Enabling Dynamics 7.4 Client & Family Psychoeducation on Addiction Science

8 Chapter 8: Evidence-Based Modalities & Therapeutic Interventions

8.1 Motivational Interviewing (MI) Principles, OARS & Change Talk 8.2 Transtheoretical Model (Stages of Change) & Matching Interventions 8.3 Cognitive-Behavioral Therapy (CBT) & Cognitive Restructuring 8.4 Trauma-Informed Care & Crisis Intervention Strategies

9 Chapter 9: Pharmacotherapy & Relapse Prevention Strategies

9.1 Addiction Pharmacotherapy (MAT/MAR: Methadone, Buprenorphine, Naltrexone, Acamprosate) 9.2 Relapse Prevention Models (Marlatt), Triggers & High-Risk Situations 9.3 Harm Reduction Principles & Overdose Prevention 9.4 Managing Co-Occurring Symptoms in Counseling

10 Chapter 10: Legal & Confidentiality Regulations

10.1 42 CFR Part 2 Federal Confidentiality Regulations & Consent Requirements 10.2 HIPAA Privacy/Security Rules vs. 42 CFR Part 2 Differences & Interplay 10.3 Medical Emergencies, Crime on Premises & Court Order Exceptions 10.4 Mandatory Child/Elder Abuse Reporting & Duty to Warn (Tarasoff)

11 Chapter 11: Professional Ethics, Boundaries & Supervision

11.1 NAADAC Code of Ethics Principles & Ethical Decision-Making Models 11.2 Professional Boundaries, Dual Relationships & Scope of Practice 11.3 Clinical Documentation Standards (SOAP, BIRP, DAP) & Record Integrity 11.4 Clinical Supervision, Counselor Burnout & Professional Wellness

4.1 Co-Occurring Psychiatric Disorders & Integrated Screening

Key Takeaways Explain This Topic AI

Approximately 50% of individuals diagnosed with a severe substance use disorder will experience a co-occurring psychiatric disorder during their lifetime, establishing co-occurring disorders (COD) as the clinical rule rather than the exception.

Integrated Dual Disorder Treatment (IDDT) models yield significantly superior clinical outcomes compared to sequential or parallel care by addressing substance use and mental health conditions simultaneously within a unified, multidisciplinary team.

Distinguishing a primary psychiatric disorder from a substance-induced disorder requires evaluating symptom onset prior to substance initiation or observing symptom persistence during 4 or more weeks of sustained abstinence.

Validated screening instruments such as the PHQ-9 (depression), GAD-7 (anxiety), and MDQ (bipolar spectrum) serve to identify symptom severity and trigger comprehensive diagnostic evaluation.

Immediate psychiatric or medical referral is mandatory when a client presents with acute psychosis, active manic states, severe cognitive impairment, or signs of life-threatening substance withdrawal.

Last updated: August 2026

4.1 Co-Occurring Psychiatric Disorders & Integrated Screening

Quick Summary: Co-occurring substance use and psychiatric disorders (COD) affect approximately half of all individuals seeking addiction treatment. Delivering effective care requires moving from historical sequential or parallel care models to Integrated Dual Disorder Treatment (IDDT). Addiction counselors must utilize DSM-5-TR differential diagnosis standards—evaluating symptom onset and persistence relative to substance exposure and 4+ weeks of abstinence—while employing standardized screeners like the PHQ-9, GAD-7, and MDQ to guide timely psychiatric referrals.

Epidemiology and Clinical Significance of Co-Occurring Disorders

Co-occurring disorders (COD)—the concurrent presence of at least one substance use disorder (SUD) and at least one mental health disorder in a single individual—represent the rule rather than the exception in behavioral healthcare. Epidemiological data from national surveys, including the National Survey on Drug Use and Health (NSDUH) and the Epidemiologic Catchment Area (ECA) study, demonstrate that approximately 50% of individuals with a severe SUD will experience a co-occurring mental illness during their lifetime. Conversely, individuals diagnosed with severe mental illnesses (such as schizophrenia, bipolar disorder, or major depressive disorder) experience substance use disorders at rates double to triple those of the general population.

Historically, treatment systems categorized these conditions into separate silos, forcing clients to navigate disconnected mental health and addiction care settings. Modern clinical science recognizes that co-occurring disorders interact dynamically: substance use frequently exacerbates psychiatric distress, while untreated psychiatric symptoms significantly elevate the risk of substance use relapse. Effective management demands master-level clinical competency in integrated assessment, differential diagnosis, and cross-system care coordination.

Evolution of Treatment Delivery Models: IDDT vs. Legacy Approaches

The conceptualization of co-occurring disorder care has evolved through three primary structural models:

Sequential Treatment (Historical): Under this outdated framework, one disorder was treated to complete resolution before treatment for the second disorder was initiated. Typically, addiction treatment centers required clients to achieve prolonged sobriety before addressing underlying depression, anxiety, or trauma. This approach frequently failed because untreated psychiatric distress routinely triggered substance relapse long before "complete resolution" could occur.

Parallel Treatment (Broker Model): In parallel treatment, the client receives services for both disorders concurrently, but from separate providers in distinct clinical systems. For example, a client attends an outpatient addiction program while simultaneously seeing an external psychiatrist or mental health therapist. This model often results in fragmented care, contradictory clinical advice, medication mismatches, and heavy burden on the client to integrate their own treatment.

Integrated Dual Disorder Treatment (IDDT) Model (Gold Standard): Integrated care combines mental health and substance use interventions into a single, seamless treatment plan delivered by a unified, cross-trained multidisciplinary team. Under the IDDT framework, clinicians address both conditions simultaneously, utilizing stage-matched interventions (e.g., combining Motivational Interviewing for addiction with Cognitive Behavioral Therapy for depression). Comprehensive research demonstrates that integrated treatment produces superior clinical outcomes, higher treatment retention, reduced hospitalizations, and improved long-term functional recovery.

Common Co-Occurring Psychiatric Conditions

Master addiction counselors must maintain deep familiarity with the clinical presentation of psychiatric disorders that frequently co-occur with substance use:

Major Depressive Disorder (MDD): Marked by persistent depressed mood, anhedonia, vegetative sleep/appetite changes, feelings of worthlessness, and suicidal ideation. Depressive disorders frequently co-occur with alcohol, sedative, and opioid use disorders.

Bipolar Spectrum Disorders (Bipolar I & II): Characterized by alternating periods of depressive episodes and manic or hypomanic states (grandiosity, decreased need for sleep, racing thoughts, hypersexuality, impulsivity). Individuals in manic or hypomanic phases frequently use central nervous system depressants or alcohol to self-medicate hyperarousal, or stimulants during depressive crashes.

Anxiety Disorders (GAD, Panic Disorder, Social Anxiety): Chronic worry, autonomic arousal, panic attacks, and avoidance behaviors. Alcohol, benzodiazepines, and cannabis are frequently utilized as maladaptive self-medication strategies for acute anxiety.

Personality Disorders (Borderline & Antisocial): Borderline Personality Disorder (BPD) features affective instability, fear of abandonment, chronic emptiness, and self-harm, strongly intersecting with polysubstance misuse. Antisocial Personality Disorder (ASPD) involves disregard for social norms, impulsivity, and deceitfulness, exhibiting high comorbidity with early-onset severe SUD.

DSM-5-TR Differential Diagnosis Guidelines

A central challenge in addiction assessment is distinguishing a primary psychiatric disorder (an independent mental health condition) from a substance-induced disorder (psychiatric symptoms caused directly by acute substance intoxication, physiological withdrawal, or neurochemical adaptations).

Diagnostic Differentiation Rules

To establish an accurate differential diagnosis, clinicians follow established DSM-5-TR guidelines:

Timeline Evaluation: Evaluate whether psychiatric symptoms preceded the onset of substance use. A documented history of depressive, manic, or psychotic episodes occurring during prolonged periods of abstinence strongly supports a primary diagnosis.

The 4-Week Abstinence Standard: Depressive, anxious, or psychotic symptoms that emerge during active substance use or acute withdrawal must be re-evaluated after 4 or more weeks of verified abstinence . Symptoms that fully resolve during sustained abstinence are classified as substance-induced. Symptoms that persist beyond 4 weeks warrant consideration as primary psychiatric disorders.

Substance Specificity: Match symptoms to known pharmacological profiles. For example, paranoia during active methamphetamine use or visual hallucinations during delirium tremens are expected substance-induced manifestations, whereas auditory hallucinations persisting long after stimulant clearance suggest a primary psychotic disorder.

Exceeding Expected Effects: Symptoms that far exceed what is typically expected from the type or amount of substance used support a primary diagnosis.

Standardized Psychiatric Screening Instruments

Systematic screening ensures early identification of co-occurring symptoms. Master addiction counselors utilize validated psychometric tools during intake:

Patient Health Questionnaire-9 (PHQ-9): A 9-item self-report tool measuring depression severity based on DSM criteria. Scores range from 0 to 27 (5-9: mild, 10-14: moderate, 15-19: moderately severe, 20-27: severe). Item 9 explicitly screens for suicidal ideation.

Generalized Anxiety Disorder-7 (GAD-7): A 7-item scale assessing anxiety symptom severity over the preceding two weeks. Scores of 5, 10, and 15 represent cutoffs for mild, moderate, and severe anxiety, respectively.

Mood Disorder Questionnaire (MDQ): A 13-item screening tool for bipolar spectrum disorders, evaluating history of hypomanic/manic symptoms, symptom co-occurrence, and functional impairment. A positive screen requires endorsement of 7+ symptoms occurring during the same time frame causing moderate-to-severe impairment.

Medical and Psychiatric Referral Triggers

While addiction counselors provide comprehensive psychosocial care, certain acute clinical presentations require immediate psychiatric or medical referral:

Acute Psychosis: Active auditory/visual hallucinations, command hallucinations, or persecutory delusions.

Manic States: Severe flight of ideas, acute grandiosity, or profound sleep deprivation.

Severe Vegetative Depression: Inability to maintain basic personal hygiene, severe malnutrition, or catatonia.

Withdrawal Complications: Signs of delirium tremens, seizures, or autonomic instability requiring medical detoxification.